Albumin-bilirubin score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis: A retrospective study

Zou, Deli; Qi, Xingshun; Zhu, Cui-Hong; Zheng, Ning; Hou, Feifei; Zhao, Jichun; Peng, Ying; Li, Jing; Deng, Han; Guo, Xiaozhong

doi:10.5152/tjg.2016.15502

Cited by 72 publications

(59 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the assessment of liver function in patients with liver cancer and treated with sorafenib, the resolution of the ALBI score is similar to that of the CTP score for patients with a CTP grade of A, whereas the ALBI grading is superior to the CTP grading for all HCC patients (21). The ALBI score has a predictive efficacy similar to that of the CTP and MELD scores in terms of predicting in-hospital mortality in LC patients with acute upper gastrointestinal bleeding and in ACLF patients with concurrent LC (22,24). In the present study, the ALBI score was compared with the CTP and MELD scores to assess their value in evaluating the liver function of patients with HBV-ACLF, HBV-LC, or HBV-HCC.…”

Section: Discussionmentioning

confidence: 78%

“…The ALBI score may be used to evaluate the liver function damage and prognosis of patients with liver cancer (12,13). This score has been reported to have predictive value for in-hospital mortality in patients with primary biliary cirrhosis or LC combined with upper gastrointestinal bleeding (14,15). Few studies on the value of the ALBI score in assessing the conditions of liver function damage in various HBV-related liver diseases have been performed (16,17).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Value of the albumin‑bilirubin score in the evaluation of hepatitis B virus‑related acute‑on‑chronic liver failure, liver cirrhosis, and hepatocellular carcinoma

et al. 2018

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the value of the albumin-bilirubin (ALBI) score in the assessment of the disease conditions of hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF), HBV-related liver cirrhosis (HBV-LC) and HBV-related hepatocellular carcinoma (HBV-HCC). A total of 395 patients with HBV-ACLF, HBV-LC, or HBV-HCC were retrospectively studied. The ALBI, Child-Turcotte-Pugh (CTP), and Model for End-Stage Liver Disease (MELD) scores of the patients were calculated, and the relationships between the ALBI score and the CTP and MELD scores were investigated. Furthermore, the ALBI grading was tested for the evaluation of the severity and stages of HBV-ACLF, HBV-LC, and HBV-HCC, especially when classifying the clinical stages of HBV-ACLF. The mean ALBI scores of the HBV-ACLF, HBV-LC, and HBV-HCC patients were -1.17±0.55, -1.76±0.66 and -2.59±0.62, respectively; the mean CTP scores were 10.70±1. 81, 8.19±1.25 and 5.81±1.22, respectively; and the mean MELD scores were 19.93±7.44, 11.10±4.39 and 7.01±3.22, respectively. The ALBI scores were positively correlated with the CTP and MELD scores. The mean ALBI score and the frequency of grade 3 disease were higher in HBV-ACLF patients than in patients with HBV-LC or HBV-HCC. A later HBV-ACLF stage resulted in a higher frequency of ALBI grades of 3. In conclusion, ALBI scores exhibited parallel tendencies to the CTP and MELD scores in HBV-ACLF, HBV-LC, and HBV-HCC patients; thus, ALBI grading may be a simple but applicable method for the evaluation of the functional status of patients with HBV-related end-stage liver diseases.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Value of the albumin‑bilirubin score in the evaluation of hepatitis B virus‑related acute‑on‑chronic liver failure, liver cirrhosis, and hepatocellular carcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In their retrospective study of 631 patients, the authors concluded that the performance of the albumin-bilirubin (ALBI) score was comparable with that of Child-Pugh and model for end-stage liver disease (MELD) scores for predicting the in-hospital mortality of patients with acute upper gastrointestinal bleeding (GIB) and liver cirrhosis (2). However, the authors did not compare GIB with other types of decompensated cirrhosis.…”

Section: Dear Editormentioning

confidence: 99%

“…To the Editor, We thank Dr. Cardoso et al (1) for their interest in our findings that the performance of albumin-bilirubin (ALBI) score has a higher accuracy than the Child-Pugh and model for end-stage liver disease (MELD) scores for predicting the in-hospital mortality in 631 cirrhotic patients with upper gastrointestinal bleeding (GIB) but that the difference was not statistically significant (2). Similarly, Cardoso et al (1) found that the performance of the ALBI score was superior to that of the MELD and Child-Pugh scores for predicting the in-hospital, 28-day, 90-day, and 1-year mortality in 42 cirrhotic patients with GIB and that the difference between 90-day and 1-year mortality was statistically significant.…”

Section: Turk J Gastroenterol 2017; 28: 533-4mentioning

confidence: 99%

Albumin-bilirubin, Child-Pugh, and model for end-stage liver disease scores for the assessment of prognosis in cirrhotic patients

Zhu

Guo²,

Qi³

2019

Turk J Gastroenterol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Acute upper gastrointestinal bleeding in liver cirrhosis is mainly attributed to the development of variceal rupture [1][2][3][4] . The first-line choice of pharmacological therapy for the management of variceal bleeding is vasoconstrictors, including terlipressin, somatostatin, and octreotide [1][2] .…”

Section: Introductionmentioning

confidence: 99%

Should vasoconstrictors be considered in a cirrhotic patient with acute non-variceal upper gastrointestinal bleeding?

Shao

et al. 2017

Journal of Translational Internal Medicine

Self Cite

View full text Add to dashboard Cite

Varices manifest as a major etiology of upper gastrointestinal bleeding in patients with chronic liver diseases, such as liver cirrhosis and hepatocellular carcinoma. By contrast, non-variceal upper gastrointestinal bleeding is rare. Pharmacological treatment differs between patients with variceal and non-variceal bleeding. Vasoconstrictors are recommended for the treatment of variceal bleeding, rather than non-variceal bleeding. In contrast, pump proton inhibitors are recommended for the treatment of non-variceal bleeding, rather than variceal bleeding. Herein, we present a case with liver cirrhosis and acute upper gastrointestinal bleeding who had a high risk of rebleeding (i.e., Child-Pugh class C, hepatocellular carcinoma, portal vein thrombosis, low albumin, and high international normalized ratio and D-dimer). As the source of bleeding was obscure, only terlipressin without pump proton inhibitors was initially administered. Acute bleeding episode was effectively controlled. After that, an elective endoscopic examination confirmed that the source of bleeding was attributed to peptic ulcer, rather than varices. Based on this preliminary case report, we further discussed the potential role of vasoconstrictors in a patient with cirrhosis with acute non-variceal upper gastrointestinal bleeding.

show abstract

Albumin-bilirubin score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis: A retrospective study

Cited by 72 publications

References 20 publications

Value of the albumin‑bilirubin score in the evaluation of hepatitis B virus‑related acute‑on‑chronic liver failure, liver cirrhosis, and hepatocellular carcinoma

Value of the albumin‑bilirubin score in the evaluation of hepatitis B virus‑related acute‑on‑chronic liver failure, liver cirrhosis, and hepatocellular carcinoma

Albumin-bilirubin, Child-Pugh, and model for end-stage liver disease scores for the assessment of prognosis in cirrhotic patients

Should vasoconstrictors be considered in a cirrhotic patient with acute non-variceal upper gastrointestinal bleeding?

Contact Info

Product

Resources

About